FIELD: medicine.
SUBSTANCE: group of inventions relates to the field of medicine, namely, to a method for the prevention and/or treatment of atopic dermatitis, containing the introduction of an anti-IL-31RA human neutralizing antibody to a subject suffering from atopic dermatitis or predisposed to its development, in which the said anti-IL-31RA neutralizing antibody is administered according to any of the following (a)-(d): (a) administration several times to an adult subject in equal amounts at the same intervals between administration of 25 to 100 mg / body/4 weeks, 25 to 75 mg / body/4 weeks, 50 to 100 mg / body/4 weeks, or 50 to 75 mg / body/4 weeks; (b) administration several times to an adult subject in equal amounts at the same intervals between administration of 0.5 mg / kg/4 weeks; (с) administration of an initial dose to an adult subject and then constant doses in equal amounts at the same intervals between administration of 25 to 100 mg / body/4 weeks, 25 to 75 mg / body/4 weeks, 50 to 100 mg / body/4 weeks, or 50 to 75 mg / body/4 weeks, with the initial dose being different from the constant dose; and (d) administration several times to the subject child in equal amounts at the same intervals between administration of 10 to 50 mg/body/4 weeks or 10 to 40 mg/body/4 weeks, and in which the specified anti-IL-31RA-neutralizing antibody is an anti-IL-31RA antibody containing an H-chain, as specified in SEQ ID NO: 9, and an L-chain, as specified in SEQ ID NO: 10, and also refers to the use of an anti-IL-31RA human-neutralizing antibody to obtain a drug for prevention and/or treatment of atopic dermatitis.
EFFECT: group of inventions provides the identification of constant doses that effectively and stably suppress atopic dermatitis over a long period of time.
17 cl, 11 dwg, 4 tbl, 4 ex
